Nonproliferative retinopathy - Biotech, Pharma and Life Science Channel

02:27 EST 27th February 2015 | BioPortfolio

PubMed Articles [287 Associated PubMed Articles listed on BioPortfolio]

Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease.

Central serous chorioretinopathy (CSCR) is of unknown etiology and is the most common cause of retinopathy after age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Vis...

Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects.

Vascular endothelial growth factor (VEGF) is one of the main endogenous pro-angiogenic cytokines. Inhibition of the VEGF signaling pathways is an effective treatment for cancer patients. In addition, ...

Extended Follow-up of Treated and Untreated Retinopathy in Incontinentia Pigmenti: Analysis of Peripheral Vascular Changes and Incidence of Retinal Detachment.

Extended follow-up of treated and untreated retinopathy in incontinentia pigmenti (IP) has not previously been documented, to our knowledge.

A safety and feasibility study of the use of 670 nm red light in premature neonates.

Objective:Retinopathy of prematurity (ROP) is a vasoproliferative disorder of the retina affecting extremely preterm or low birth weight infants The aim of this study was to assess the feasibility and...

Therapeutic Potential of Anti-Angiogenic Multi-Target N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy.

Vascular endothelial growth factor (VEGF) blockers have been developed for the treatment of proliferative diabetic retinopathy (PDR), the leading cause of visual impairments in the working-age populat...

Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema.

Diabetic cystoid macular oedema (CMO) is a condition which involves fluid accumulation in the inner portion of the retina. It often follows changes in retinal blood vessels which enhance the fluid to ...

Progression of diabetic retinopathy after bariatric surgery.

To assess the impact of bariatric surgery on the progression of diabetic retinopathy in patients with Type 2 diabetes.

AGEs Promote Oxidative Stress and Induce Apoptosis in Retinal Pigmented Epithelium Cells RAGE-dependently.

Advanced glycation end products (AGEs) are extremely accumulated in diabetes mellitus, particularly in retinal vascular and epithelium cells, and are confirmed to contribute to diabetic retinopathy (D...

CSAX: Characterizing Systematic Anomalies in eXpression Data.

Methods for translating gene expression signatures into clinically relevant information have typically relied upon having many samples from patients with similar molecular phenotypes. Here, we address...

Demographic Disparities Among Medicare Beneficiaries with Type 2 Diabetes Mellitus in 2011: Diabetes Prevalence, Comorbidities, and Hypoglycemia Events.

This study describes demographic characteristics, comorbidities, and hypoglycemia events in patients with type 2 diabetes mellitus (T2DM) identified using 2011 Medicare 5% Standard Analytical Files. A...

News Articles [136 Associated News Articles listed on BioPortfolio]

Theratechnologies Announces Financial Results for Fiscal Year 2014

MONTREAL, CANADA -- (Marketwired) -- 02/26/15 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the year ended November 30, 2014. Fiscal year 2014 fi...

Microvascular Complications and Foot Care

Read the American Diabetes Association recommendations for screening and management of diabetic retinopathy, nephropathy, neuropathy, and foot care. Diabetes Care

Eye Protector™ by The Synergy Company™ Answers the Call for a Comprehensive Eye Health Vitamin

With concerns over eye health on the rise, the latest nutritional supplement by The Synergy Company™ is a big leap forward. Moab, Utah (PRWEB) February 24, 2015 Eye Protector™ could not have come...

Evaluating Drugs to Improve Vision In Diabetic Macular Edema

A national study led by Northwestern Medicine shows the drug Eylea is superior for improving the eyesight of persons with poor vision due to diabetic macular edema, a major cause of vision loss from d...

Eylea beats rivals in government-sponsored head-to-head trial

Results from a trial comparing three treatments for serious eye disease have shown that Regeneron and Bayer's Eylea is the most effective.The trial was sponsored by the US government-funded National I...

Johns Hopkins Helps lead discovery on efficacy and safety of 3 drugs for treating DME

(Johns Hopkins Medicine) A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network t...

Johns Hopkins Helps to lead discovery on efficacy and safety of 3 drugs for treating DME

(Johns Hopkins Medicine) A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network t...

Alimera Sciences To Host ILUVIEN® Live Webinar Launch Event

ATLANTA, Feb. 17, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescriptio...

Independent Living Centers Pave The Way For Older Individuals With Blindness To Live Independently

SACRAMENTO, Calif., Feb. 11, 2015 /PRNewswire/ -- More than ever, older Californians are facing the threat of blindness from age-related eye diseases such as diabetic retinopathy, macular degeneration...

Hospira, Pfenex in deal for Lucentis biosimilar

Pfenex Inc. (NYSE-M:PFNX) jumped $1.10 (16%) to $8 on Tuesday after partnering with Hospira Inc. (NYSE:HSP) to collaborate on the development of PF-582, Pfenex's biosimilar of Lucentis rani

Events [0 Results]

None

Companies [6 Associated Companies listed on BioPortfolio]

Acucela Inc.

Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye di...

Optos plc

Optos plc is a leading medical retinal imaging technology company. Both eye and non-eye diseases often first exhibit in the periphery of the retina. These are very difficult to de...

Promedior, Inc.

Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By...

NormOxys, Inc.

NormOxys is developing a novel class of small molecule drugs, oxyrens, which enhance the body’s ability to deliver oxygen more efficiently to diseased tissues with oxygen def...

Acucela

Acucela Inc. (www.acucela.com) is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for...

Allegro Ophthalmics, LLC

With more than 100 years of combined experience in vision science and medicine, the leadership team at Allegro Ophthalmics, LLC is establishing Integrin Peptide Therapy as the ...

Clinical Trials [171 Associated Clinical Trials listed on BioPortfolio]

Family Myopia Study

This study will try to identify the gene or genes responsible for myopia (nearsightedness) and to examine the relationship between myopia and near work. Myopia is the most common eye disor...

Retinal Thickness Analysis Using Optical Coherence Tomography

The main objective of this study is to characterize and correlate diabetic macular edema (DME), i.e. increased retinal thickness, measured by Optical Coherence Tomograph (OCT), and retinal...

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

This study is to see whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than treating diabetic retinal swelling with ranibizumab injectio...

Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment

This study evaluates a new investigational treatment regimen of three consecutive monthly doses of ranibizumab followed by an as-needed treatment regimen, with monthly follow-up for the fi...

Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER)

To characterise phenotypes of Non Proliferative Diabetic Retinopathy (NPDR) progression using multimodal testing/imaging procedures.

Intravitreal Aflibercept Injection for Radiation Retinopathy

The purpose of this study is to assess the safety of intravitreal aflibercept injection - in the treatment of macular edema associated with retinopathy secondary to previous radiation ther...

Effects of Caloric Restriction in Obesity and Type 2 Diabetes

The study investigates whether a long-term 25% caloric restriction can prevent onset and/or progression of renal function deterioration, retinal involvement and cardiovascular complication...

Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema

This pilot study aims to establish that treatment with near infrared light (NIR) reduces diabetic macular oedema in patients suffering diabetic retinopathy by exerting a positive beneficia...

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (the STOP-ROP Multicenter Trial)

To test the efficacy, safety, and costs of providing supplemental oxygen in moderately severe retinopathy of prematurity (prethreshold ROP).

Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) - Outcome Study of Cryotherapy for Retinopathy of Prematurity

To determine the safety and efficacy of trans-scleral cryotherapy of the peripheral retina in certain low birth-weight infants with retinopathy of prematurity (ROP) for reducing blindness ...

Medical and Biotech [MESH] Definitions

A bilateral retinopathy occurring in premature infants treated with excessively high concentrations of oxygen, characterized by vascular dilatation, proliferation, and tortuosity, edema, and retinal detachment, with ultimate conversion of the retina into a fibrous mass that can be seen as a dense retrolental membrane. Usually growth of the eye is arrested and may result in microophthalmia, and blindness may occur. (Dorland, 27th ed)

Degenerative changes to the RETINA due to HYPERTENSION.

A drug used to reduce hemorrhage in diabetic retinopathy.

Removal of the whole or part of the vitreous body in treating endophthalmitis, diabetic retinopathy, retinal detachment, intraocular foreign bodies, and some types of glaucoma.

Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.

Search BioPortfolio:
Loading
Advertisement
Advertisement
review and buy Nonproliferative retinopathy market research data and corporate reports here

Channels Quicklinks